Koch M, Uyttenboogaart M, van Harten A, De Keyser J
University Medical Center Groningen, Department of Neurology, Groningen, The Netherlands.
Mult Scler. 2008 Jul;14(6):799-803. doi: 10.1177/1352458508089361. Epub 2008 Jun 23.
To investigate factors associated with the risk of secondary progression in relapsing-remitting onset multiple sclerosis (MS).
We used Kaplan-Meier survival analyses and a multivariable Cox regression model to estimate the influence of the factors: gender, age at disease onset, use of immunomodulatory drugs (IMD), and clinical manifestation at disease onset on the time to secondary progression in a hospital-based cohort of 571 MS patients with a relapsing-remitting onset.
Gender and onset manifestation had no significant influence on the timing of secondary progression. A higher age at disease onset was associated with a shorter time to secondary progression (multivariable hazard ratio per year increase: 1.02, 95% CI:1.01 - 1.03). The use of IMD was associated with a longer time to secondary progression (multivariable hazard ratio: 0.30, 95% CI: 0.15 - 0.61).
The inverse relationship between age at disease onset and onset of secondary progression is in keeping with previous natural history studies. The beneficial effect of IMD treatment on the time to secondary progression should be taken as hypothesis-generating rather than as proof of a treatment effect, and needs to be further evaluated in well-designed randomised controlled trials.
探讨复发缓解型多发性硬化(MS)继发进展风险的相关因素。
我们采用Kaplan-Meier生存分析和多变量Cox回归模型,评估性别、发病年龄、免疫调节药物(IMD)的使用以及发病时的临床表现等因素对571例复发缓解型MS住院患者继发进展时间的影响。
性别和发病表现对继发进展的时间无显著影响。发病年龄越高,继发进展时间越短(每增加一岁的多变量风险比:1.02,95%置信区间:1.01 - 1.03)。使用IMD与继发进展时间延长相关(多变量风险比:0.30,95%置信区间:0.15 - 0.61)。
发病年龄与继发进展起始之间的负相关关系与先前的自然史研究一致。IMD治疗对继发进展时间的有益作用应被视为产生假设,而非治疗效果的证据,需要在精心设计的随机对照试验中进一步评估。